This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
It’s earnings time again and investors are back to watching the quarterly releases closely. This time as well, we expect the Energy sector to contribute the maximum to earnings growth for the S&P 500.
COP APC CTLR MRO CLR AEUA EOG
Royal Dutch Shell plc (RDS.A - Free Report) has entered into an accord with Nigerian National Petroleum Corporation and other two firms for developing the natural gas reserves of Nigeria, per media reports.
RDS.B RDS.A XOM CTLR RYDBF MUR.WI MUR RDSB CLR RDSA RYDAF
On Jul 7, Penn Virginia Corporation (PVAC - Free Report) was upgraded to a Zacks Rank #1 (Strong Buy), implying that the stock will significantly outperform the broader U.S. equity market over the next one to three months.
PVAC CTLR ADI PVAYQ MUR.WI PVA MUR MRO CLR
On Jul 7, EOG Resources, Inc. (EOG - Free Report) has been upgraded to a Zacks Rank #1 (Strong Buy), implying that the stock will significantly outperform the broader U.S. equity market over the next one to three months.
CTLR MUR.WI MUR MRO CLR EOG
Transocean Ltd. (RIG - Free Report) announced the start of offering senior notes to potential investors. The notes, with aggregate pricing amount of $600 million, will carry an interest rate of 6.125% and are expected to mature by 2025.
CTLR MUR.WI MUR MRO CLR RIG SGAZF
Chicago, IL – July 10, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Apache Corp. (APA - Free Report) , Continental Resources, Inc. (CLR - Free Report) , KMG Chemicals, Inc. (KMG - Free Report) , ZAGG Inc (ZAGG - Free Report) and AbbVie Inc.
APA KMG CTLR LXFR HEAR ABBV CLR ZAGG ABBV NCS SXC
Energen Corporation (EGN - Free Report) recently provided an update that Carl Icahn has boosted its stake holding in the company. This time, the activist investor raised its ownership from 6.9% to 7.5%.
CTLR EGN MUR.WI MUR MRO CLR
Atlantica Yield plc (AY - Free Report) : This company that owns, and manages renewable energy natural gas, power, electric transmission lines, and water assets has seen the Zacks Consensus Estimate for its current year earnings increasing 26.1% over the last 60 days.
AY BOE CTLR CLR BA
A common investing misconception is that all exploration and production players will gain from the current rally in crude prices. However, all oil plays in the United States are not positioned to capitalize on the recovering commodity.
COP WLL MRO CLR
LONDON, July 2 — President Donald Trump’s request to Saudi Arabia that it increase oil production shows how few options he has to lower prices at the gasoline pumps ahead of elections that are key to continuing his agenda.
31m - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
1h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
22h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to CLR / Continental Resources, Inc. on message board site Silicon Investor.
as of ET